Amicus Therapeutics Stock Volatility Indicators Average True Range

Methodology

Unless otherwise specified, financial data for Amicus Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Amicus (USA Stocks:FOLD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Amicus Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Amicus Therapeutics has active sell-side coverage. Source-validated coverage currently shows 7 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, among others. Updates may occur throughout the day.

This content is curated and reviewed by: